NFKB1 and breast carcinoma: In basal-like breast cancer, Epalrestat disrupted the Twist2–AKR1B1–NF-κB positive feedback loop, restored E-cadherin expression, reduced PGF2A production, and markedly suppressed cell migration, invasion, and lung metastasis in vivo [46].